Document is current
Any future updates will be listed below
-
Authors
Fourie, Anne M.
Cheng, Xiaoli
Chang, Leon
Greving, Carrie
Li, Xinyi
Knight, Beverly
Polidori, David
Patrick, Aaron
Bains, Trpta
Steele, Ruth
Allen, Samantha J.
Patch, Raymond J.
Sun, Chengzao
Somani, Sandeep
Bhandari, Ashok
Liu, David
Huie, Keith
Li, Shu
Rodriguez, Michael A.
Xue, Xiaohua
Kannan, Arun
Kosoglou, Teddy
Sherlock, Jonathan P.
Towne, Jennifer
Holland, M. Claire
Modi, Nishit B.
-
Funding
Funding for this research was provided by:
Janssen Research and Development
Protagonist Therapeutics, Inc
- License Information
-
More Information
Article History
Received: 13 December 2023
Accepted: 10 July 2024
First Online: 30 July 2024
Competing interests
: AMF, LC, CG, BK, DP, AP, TB, RS, SJA, SS, MAR, AK, TK, and MCH are employees of Janssen Research & Development, LLC; employees may own stock/stock options in Johnson & Johnson, of which Janssen is a subsidiary. AB, SL, and NBM are employees of Protagonist Therapeutics, Inc and may own stock/stock options in the company. XC, DL, and KH were employees of Protagonist at the time these studies were conducted. XC is currently an employee of Anwita Biosciences and owns stock in Protagonist. KH is a Cytokinetics employee. XL, XX, RJP, CS, JPS and JT were employees of Janssen Research & Development, LLC, at the time these studies were conducted; XL is currently an employee of Takeda and JT is currently an employee of Vir Biotechnology.
